BlueCross BlueShield
Federal Employee Program
Blue Cross Blue Shield Association
750 9th St NW, Suite 900
Washington, D.C. 20001
1-800-624-5060
Fax 1-877-378-4727

5.01.082

Section:	Prescription Drugs	**Effective Date:**	July 1, 2026
Subsection:	Anti-infective Agents	**Original Policy Date:**	December 12, 2025
Subject:	Orlynvah	**Page:**	1 of 4

Last Review Date: June 11, 2026

Orlynvah

Description

Orlynvah (sulopenem etzadroxil and probenecid)

Background
Orlynvah is a combination of sulopenem etzadroxil, a penem antibacterial drug and probenecid, a renal tubular inhibitor. Probenecid inhibits organic anion transporter 3 (OAT3)-mediated renal clearance of sulopenem, resulting in increased plasma concentrations of sulopenem (1).

Regulatory Status
FDA-approved indications: Orlynvah, a combination of sulopenem etzadroxil, a penem antibacterial, and probenecid, a renal tubular transport inhibitor, is indicated for the treatment of uncomplicated urinary tract infecions (uUTI) caused by designated microorganisms *Escherichia coli*, *Klebsiella pneumoniae*, or *Proteus mirabilis* in adult women who have limited or no alternative oral antibacterial treatment options (1).

Limitations of Use: (1)
Orlyvah is not indicated for the treatment of:

- Complicated urinary tract infections (cUTI) or as step-down treatment after intravenous antibacterial treatment of cUTI.
- Complicated intra-abdominal infections (cIAI) or as step-down treatment after intravenous antibacterial treatment of cIAI.

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Orlynvah and other antibacterial drugs, Orlynvah should be used only to treat uUTI that are proven or strongly suspected to be caused by susceptible bacteria. Culture and susceptibility information should be utilized in selecting or modifying antibacterial therapy (1).

Orlynvah is contraindicated in patients with: (1)

- Known blood dyscrasias.
- Known uric acid kidney stones.
- Concomitant use of ketorolac tromethamine.

Orlynvah contains warnings regarding hypersensitivity reactions, *Clostridioides difficile*-associated diarrhea, risk of uric acid kidney stone development, exacerbation of gout, and development of drug-resistant bacteria (1).

The safety and effectiveness of Orlynvah in pediatric patients less than 18 years of age have not been established (1).

Related policies
Baxdela, Nuzyra, Xenleta, Sivextro, Zyvox

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Orlynvah may be considered **medically necessary** if the conditions indicated below are met.

Orlynvah may be considered **investigational** for all other indications.

Prior-Approval Requirements

Patients who have filled a course of nitrofurantoin, sulfamethoxazole/trimethoprim, or fosfomycin in the last 30 days are exempt from these Prior Authorization (PA) requirements.

Age 18 years of age or older

Gender Female

Diagnosis

Patient must have the following:

1. Uncomplicated urinary tract infection (uUTI)
    a. Caused by *Escherichia coli*, *Klebsiella pneumoniae*, or *Proteus mirabilis*
    b. Caused by or strongly suspected to be caused by susceptible bacteria based on culture and susceptibility, local epidemiology, or susceptibility patterns
    c. Patient has limited or no alternative oral antibacterial treatment options

Prior – Approval *Renewal* Requirements

Same as above

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity 10 tablets

Duration 30 days

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Orlynvah, a combination of sulopenem etzadroxil, a penem antibacterial, and probenecid, a renal tubular transport inhibitor, is indicated for the treatment of uncomplicated urinary tract infecions (uUTI) caused by designated microorganisms *Escherichia coli*, *Klebsiella pneumoniae*, or *Proteus mirabilis* in adult women who have limited or no alternative oral antibacterial

treatment options. The safety and effectiveness of Orlynvah in pediatric patients less than 18 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Orlynvah while maintaining optimal therapeutic outcomes.

References

1. Orlynvah [package insert]. Chicago, IL: Iterum Therapeutics U.S. Limited; March 2025.

Policy History

Date	Action
January 2026	Annual review. Addition to PA
June 2026	Annual review

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on June 11, 2026 and is effective on July 1, 2026.